Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer

Biomarker-Driven Radiation Dose Reduction After TORS in Patients With HPV-Positive Oropharyngeal Cancer

This phase II trial tests whether reduced dose radiation therapy after transoral robotic surgery works in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer. HPV positive oropharyngeal cancer has a better prognosis than oropharyngeal cancer not caused by HPV. A standard of care treatment for HPV positive oropharyngeal cancer is transoral robotic surgery followed by radiation therapy. However, this treatment is associated with many long-term side effects including difficulty swallowing. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving reduced dose radiation therapy after transoral robotic surgery may improve swallowing outcomes and quality of life compared to standard of care dose radiation therapy after transoral robotic surgery.

Study Overview

• Status: Recruiting
• Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal HPV-Positive Squamous Cell Carcinoma
• Intervention / Treatment: Radiation: Radiation Therapy

Detailed Description

PRIMARY OBJECTIVE:

I. To evaluate swallow function among post-operative circulating tumor HPV deoxyribonucleic acid (ctHPVDNA)-negative patients treated with reduced intensity adjuvant radiation therapy (RT) doses as compared to historical controls from ECOG 3311.

SECONDARY OBJECTIVES:

I. Evaluate progression free survival (PFS), overall survival (OS), and locoreginal control (LRC) among post-operative ctHPVDNA-negative patients treated with reduced adjuvant RT doses.

II. Evaluate PFS among post-operative ctHPVDNA-positive patients treated with standard of care adjuvant therapy.

OUTLINE:

Patients who are ctHPVDNA negative after surgery undergo reduced dose radiation therapy for 3 weeks (15 treatments). Patients who are ctHPVDNA positive after surgery undergo standard of care radiation therapy.

After completion of study treatment, patients are followed up at 3, 6, 12, 18, and 24 months.

• Study Type: Interventional
• Enrollment (Estimated): 33
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: James Bates, MD; Phone Number: 404-778-3473; Email: james.edward.bates@emory.edu

Study Locations

• United States
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Not yet recruiting
      • Emory University Hospital/Winship Cancer Institute
      • Contact: Allyson Anderson; Phone Number: 404-686-0239; Email: allyson.anderson@emory.edu
      • Principal Investigator: James E. Bates, MD
    • Atlanta, Georgia, United States, 30308
      • Recruiting
      • Emory University Midtown Hospital
      • Contact: Allyson Anderson; Phone Number: 404-686-0239; Email: allyson.anderson@emory.edu
      • Principal Investigator: James E Bates, MD
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Not yet recruiting
      • Vanderbilt University Medical Center
      • Contact: Michael C Topf, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age >= 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%).
• Life expectancy > 12 weeks as determined by the Investigator.

• Has diagnosis of HPV-associated squamous cell carcinoma of the oropharynx

  • HPV positive either via p16 status or via in situ hybridization
  • This includes patients with HPV positive squamous cell carcinoma of an unknown primary of the head and neck presumed to be of oropharyngeal origin who have undergone ipsilateral palatine and lingual tonsillectomies.
• pT1-2, pN0-1, cM0 disease.
• Positive ctHPVDNA titer prior to surgery.
• =< 10 pack-year smoking history.
• Completed transoral robotic surgery (TORS) oropharyngectomy and at least ipsilateral neck dissection by an Emory otolaryngologist.

• Pathology must demonstrate at least one of the follow intermediate risk factors:

  • Close margin (1 - 4 mm)
  • Perineural invasion
  • Lymphovascular space invasion
  • 2 - 4 positive lymph nodes without extranodal extension (ENE)
  • A single positive lymph node > 3 cm in size, without ENE
• Pathology cannot demonstrate > 4 positive lymph nodes, ENE, or a positive final margin (defined as < 1 mm). Margins that have been subsequently cleared are allowed.
• Radiation increases the risk of birth defects. For this reason, females of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy.
• FCBP and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 12 months after completion of radiation. A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months.
• Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.
• Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

Exclusion Criteria:

• Patients with a prior history of malignancy in the last two years (excluding non- melanomatous skin cancer).
• Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier (i.e., have residual toxicities > grade 1).
• Patients who are receiving any other investigational agents or an investigational device within 21 days before administration of first dose of study drugs.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Significant cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to start of study therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association class 3 or 4 congestive heart failure; or uncontrolled grade >= 3 hypertension (diastolic blood pressure >= 100 mmHg or systolic blood pressure >= 160 mmHg) despite antihypertensive therapy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment (reduced dose radiation therapy); Patients who are ctHPVDNA negative after surgery undergo reduced dose radiation therapy for 3 weeks (15 treatments). Patients who are ctHPVDNA positive after surgery undergo standard of care radiation therapy.	Radiation: Radiation Therapy; Undergo reduced dose radiation therapy; Other Names: Cancer Radiotherapy; ENERGY_TYPE; Irradiate; Irradiated; Irradiation; Radiation; Radiation Therapy, NOS; Radiotherapeutics; Radiotherapy; RT; Therapy, Radiation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Swallowing Function Mean	Will be assessed by the MD Anderson Dysphagia Index (MDADI) composite score (range 20 - 100, higher is better). Mean MDADI composite score will be reported at one year, along with a 95% confidence interval for the mean.	At 1 year post surgery
Swallowing Function T-Test	A one-sample t-test will be conducted to compare the 1-year MDADI composite score with the null value of 79.1.	At 1 year post surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS)	Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. A two-year PFS is of particular interest to compare to historical data (ECOG 3311), this specific estimate and its 95% confidence interval will be estimated from the Kaplan-Meier curve and compared descriptively to the same estimate from ECOG 3311 Arm B.	From study entry to the earliest disease progression or death from any cause, assessed up to 24 months
Overall Survival (OS)	A two-year OS is of particular interest to compare to aforementioned historical controls; this specific estimate and its 95% confidence interval will be obtained from the Kaplan-Meier curve and compared descriptively to the same estimate from ECOG 3311 Arm B.	From study entry to death due to any cause, assessed up to 24 months
Locoregional Control (LRC)- Six Month	LRC will be defined as the percentage of patients at a given timepoint that have not experienced recurrence of their disease at the primary site of their tumor in the oropharynx or in their neck. This will be analyzed in a similar manner to OS and PFS and compared to historical controls from ECOG 3311 Arm B.	At 6 months
Locoregional Control (LRC)- Two Year	LRC will be defined as the percentage of patients at a given timepoint that have not experienced recurrence of their disease at the primary site of their tumor in the oropharynx or in their neck. This will be analyzed in a similar manner to OS and PFS and compared to historical controls from ECOG 3311 Arm B.	At 2 years
Quality of Life (QoL) - MD Anderson Symptom Inventory	Quality of Life endpoints that are routinely collected and will continue to be collected on participants on this trial - MD Anderson Symptom Inventory - Head and Neck (MDASI-HN), Michigan Xerostomia, European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L).	At 2 years
Quality of Life (QoL) - Michigan Xerostomia	Quality of Life endpoints that are routinely collected and will continue to be collected on participants on this trial - Michigan Xerostomia	At 2 years
Quality of Life (QoL) - European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L)	Quality of Life endpoints that are routinely collected and will continue to be collected on participants on this trial - European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L)	At 2 years

Collaborators and Investigators

• Sponsor: Emory University
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: James E Bates, MD, Emory University Hospital/Winship Cancer Institute

Study record dates

Study Major Dates

• Study Start (Actual): June 6, 2022
• Primary Completion (Estimated): May 5, 2025
• Study Completion (Estimated): May 5, 2026

Study Registration Dates

• First Submitted: May 17, 2022
• First Submitted That Met QC Criteria: May 20, 2022
• First Posted (Actual): May 24, 2022

Study Record Updates

• Last Update Posted (Actual): August 9, 2023
• Last Update Submitted That Met QC Criteria: August 8, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Carcinoma; Oropharyngeal Neoplasms
• Other Study ID Numbers: STUDY00004187; P30CA138292 (U.S. NIH Grant/Contract); NCI-2022-02855 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); WINSHIP5566-22 (Other Identifier: Emory University Hospital/Winship Cancer Institute)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No